However, in-depth analyses indicate that clinical benefits are limited in patients with low PD-L1 expression, and treatment-related toxicity—such as immune-related pneumonia, hepatitis, and chemotherapy-induced myelosuppression—is increased (13). This evidence concerns the gene CD274 and hepatitis A virus infection.